Gain Therapeutics
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug candidate GT-02287 for the treatment of Parkinson's disease and other neurodegenerative diseases is currently being evaluated in a Phase 1 clinical trial. With its Magellan drug discovery platform, Gain is transforming drug discovery by integrating Al, physics-based methods and supercomputing power to discover novel allosteric binding sites and potential first-in-class drug candidates from on-demand libraries with 50 billion compounds in less than 3 months.
Gain Therapeutics Presents New Preclinical Data of Drug Candidate
Gain Therapeutics
Gain Therapeutics: A True Revolution In Drug Development (NASDAQ
Gain Therapeutics' Small Molecule Approach for CNS Diseases
Behind the scenes of Gain Therapeutics COO: Matthias Alder
Gain Therapeutics (@GainThera) / X
Gwen Melincoff - Gain Therapeutics
GANX - Gain Therapeutics, Inc. Stock - Stock Price, Institutional
Gain Therapeutics raised $46 million through Nasdaq listing
Success story interview with Dr. Manolo Bellotto, Gain
Gain Therapeutics Stock: Shares Are Surprisingly Good Value